Total Payments
$29,346
2022 Payments
$2,210
Companies
10
Transactions
36
Medicare Patients
346
Medicare Billing
$16,170
Payment Breakdown by Category
Consulting$12,540 (42.7%)
Travel$11,908 (40.6%)
Research$3,031 (10.3%)
Other$1,000.00 (3.4%)
Food & Beverage$866.99 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,540 | 10 | 42.7% |
| Travel and Lodging | $11,908 | 13 | 40.6% |
| Unspecified | $3,031 | 4 | 10.3% |
| Honoraria | $1,000 | 1 | 3.4% |
| Food and Beverage | $866.99 | 8 | 3.0% |
Payments by Type
General
$26,315
32 transactions
Research
$3,031
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences Inc | $13,911 | 13 | $0 (2017) |
| Lupin Inc. | $5,128 | 8 | $0 (2018) |
| SCYNEXIS, Inc. | $2,210 | 2 | $0 (2022) |
| Astellas Pharma Global Development | $2,031 | 3 | $0 (2018) |
| BioFire Diagnostics, LLC | $1,520 | 4 | $0 (2021) |
| Sandoz Inc. | $1,430 | 1 | $0 (2017) |
| Becton, Dickinson and Company | $1,115 | 2 | $0 (2018) |
| HOLOGIC INC | $1,000 | 1 | $0 (2017) |
| AMAG Pharmaceuticals, Inc. | $500.00 | 1 | $0 (2020) |
| New American Therapeutics, Inc. | $500.00 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,210 | 2 | SCYNEXIS, Inc. ($2,210) |
| 2021 | $2,020 | 5 | BioFire Diagnostics, LLC ($1,520) |
| 2020 | $500.00 | 1 | AMAG Pharmaceuticals, Inc. ($500.00) |
| 2018 | $6,405 | 11 | Lupin Inc. ($5,128) |
| 2017 | $18,210 | 17 | Gilead Sciences Inc ($13,911) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/04/2022 | SCYNEXIS, Inc. | — | Food and Beverage | In-kind items and services | $210.48 | General |
| 07/15/2022 | SCYNEXIS, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 10/21/2021 | New American Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 05/13/2021 | BioFire Diagnostics, LLC | FilmArray (Device) | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| Category: Clinical Diagnostics | ||||||
| 05/13/2021 | BioFire Diagnostics, LLC | Film Array (Device) | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| Category: Clinical diagnostic | ||||||
| 04/23/2021 | BioFire Diagnostics, LLC | FilmArray (Device) | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| Category: Clinical Diagnostics | ||||||
| 04/23/2021 | BioFire Diagnostics, LLC | Film Array (Device) | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| Category: Clinical diagnostic | ||||||
| 02/05/2020 | AMAG Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/06/2018 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $162.63 | Research |
| Study: A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections • Category: INFECTIOUS DISEASES | ||||||
| 09/10/2018 | Becton, Dickinson and Company | — | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| 08/14/2018 | Becton, Dickinson and Company | — | Food and Beverage | In-kind items and services | $114.66 | General |
| 07/02/2018 | Lupin Inc. | SOLOSEC (Drug) | Food and Beverage | In-kind items and services | $138.90 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 07/02/2018 | Lupin Inc. | SOLOSEC (Drug) | Food and Beverage | In-kind items and services | $73.10 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 07/02/2018 | Lupin Inc. | SOLOSEC (Drug) | Food and Beverage | In-kind items and services | $68.76 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 07/02/2018 | Lupin Inc. | SOLOSEC (Drug) | Food and Beverage | In-kind items and services | $58.10 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 05/01/2018 | Lupin Inc. | SOLOSEC (Drug) | Consulting Fee | Cash or cash equivalent | $4,030.00 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 05/01/2018 | Lupin Inc. | SOLOSEC (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 04/21/2018 | Lupin Inc. | SOLOSEC (Drug) | Travel and Lodging | In-kind items and services | $35.64 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 04/04/2018 | Lupin Inc. | SOLOSEC (Drug) | Travel and Lodging | In-kind items and services | $679.60 | General |
| Category: OBSTETRICSGYNECOLOGY | ||||||
| 12/12/2017 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $433.95 | Research |
| Study: 9766-CL-0105 • Category: INFECTIOUS DISEASES | ||||||
| 06/01/2017 | HOLOGIC INC | Aptima (Device) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: ABCTV01-SP-01 • Category: Diagnostics | ||||||
| 05/30/2017 | Gilead Sciences Inc | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 05/06/2017 | Gilead Sciences Inc | — | Travel and Lodging | In-kind items and services | $613.08 | General |
| 05/05/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $132.15 | General |
| 05/05/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $70.84 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections | Astellas Pharma Global Development | $1,435 | 1 |
| ABCTV01-SP-01 | HOLOGIC INC | $1,000 | 1 |
| 9766-CL-0105 | Astellas Pharma Global Development | $433.95 | 1 |
| A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections | Astellas Pharma Global Development | $162.63 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 84 | 163 | $10,670 | $4,314 |
| 2022 | 4 | 94 | 144 | $9,142 | $3,747 |
| 2021 | 4 | 91 | 154 | $9,730 | $4,477 |
| 2020 | 4 | 77 | 123 | $11,872 | $3,631 |
Total Patients
346
Total Services
584
Medicare Billing
$16,170
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 41 | $9,266 | $3,661 | 39.5% |
| 87210 | Smear for infectious agents | Office | 2023 | 23 | 45 | $540.00 | $256.50 | 47.5% |
| 87101 | Fungal culture (mold or yeast) of skin, hair, or nail | Office | 2023 | 18 | 31 | $496.00 | $234.36 | 47.3% |
| 83986 | Body fluid ph level | Office | 2023 | 23 | 46 | $368.00 | $161.46 | 43.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 35 | $7,910 | $3,172 | 40.1% |
| 87210 | Smear for infectious agents | Office | 2022 | 26 | 42 | $504.00 | $241.08 | 47.8% |
| 87101 | Fungal culture (mold or yeast) of skin, hair, or nail | Office | 2022 | 20 | 24 | $384.00 | $182.31 | 47.5% |
| 83986 | Body fluid ph level | Office | 2022 | 27 | 43 | $344.00 | $151.85 | 44.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 37 | $8,362 | $3,861 | 46.2% |
| 87101 | Fungal culture (mold or yeast) of skin, hair, or nail | Office | 2021 | 21 | 33 | $528.00 | $239.39 | 45.3% |
| 87210 | Smear for infectious agents | Office | 2021 | 25 | 42 | $504.00 | $233.09 | 46.2% |
| 83986 | Body fluid ph level | Office | 2021 | 25 | 42 | $336.00 | $143.38 | 42.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 26 | $7,332 | $2,344 | 32.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 15 | $3,450 | $903.79 | 26.2% |
| 87210 | Smear for infectious agents | Office | 2020 | 24 | 41 | $708.00 | $237.42 | 33.5% |
| 83986 | Body fluid ph level | Office | 2020 | 24 | 41 | $382.00 | $146.08 | 38.2% |
About Dr. Jack Sobel, MD
Dr. Jack Sobel, MD is a Internal Medicine healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184664088.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Sobel, MD has received a total of $29,346 in payments from pharmaceutical and medical device companies, with $2,210 received in 2022. These payments were reported across 36 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($12,540).
As a Medicare-enrolled provider, Sobel has provided services to 346 Medicare beneficiaries, totaling 584 services with total Medicare billing of $16,170. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Detroit, MI
- Active Since 06/08/2006
- Last Updated 11/10/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184664088
Products in Payments
- SOLOSEC (Drug) $5,128
- Cresemba (Drug) $1,435
- Aptima (Device) $1,000
- Film Array (Device) $760.00
- FilmArray (Device) $760.00
- CRESEMBA (Drug) $596.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Detroit
Randy Lieberman, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP
Internal Medicine — Payments: $708,561
Internal Medicine $708,561
Shirish Gadgeel, Md, MD
Internal Medicine — Payments: $563,542
Internal Medicine $563,542
Pedro Villablanca Spinetto, M.d, M.D
Internal Medicine — Payments: $480,267
Internal Medicine $480,267
Dr. Mir Basir, D.o, D.O
Internal Medicine — Payments: $415,569
Internal Medicine $415,569
Dr. Ammar Sukari, M.d, M.D
Internal Medicine — Payments: $371,746
Internal Medicine $371,746